Boston Scientific's shares ($BSX) experienced a significant 9% drop midday following reports of problems with the company's pacemaker batteries. Further weighing on the stock, WATCHMAN data revealed a nuance of higher-than-expected stroke risk, despite also supporting long-term adoption by meeting primary endpoints and demonstrating a 45% reduction in bleeding compared to NOACs. Analysts recommended selling on the news in the near term, though the data still indicated long-term adoption potential. Amid these developments, Boston Scientific also received positive news with FDA clearance for its Asurys™ Fluid Management System.
Boston Scientific's shares plummeted due to pacemaker battery concerns and nuanced WATCHMAN data highlighting stroke risks, even as the company secured FDA clearance for another product. Analysts advise near-term selling, yet the WATCHMAN data still indicates long-term adoption potential.
Agreed-upon facts
Key Developments Impacting Boston Scientific
Where narratives collide
No material split surfaced for this cluster—sources align on the core read.
Where sources say this may head next
Near-term vs. Long-term Market Outlook